Insight

Integrating androgen deprivation therapy with metastasis-directed therapy leads to improved progression-free survival – IOSI Oncology Institute of Southern Switzerland – EOC

Photo taken from IOSI Oncology Institute of Southern Switzerland - EOC/LinkedIn

Apr 7, 2024, 23:57

Integrating androgen deprivation therapy with metastasis-directed therapy leads to improved progression-free survival – IOSI Oncology Institute of Southern Switzerland – EOC

IOSI Oncology Institute of Southern Switzerland – EOC made the following post on LinkedIn:

“New publication! A collaborative research effort involving physicians from the IOSI Istituto Oncologico della Svizzera Italiana – EOC has now been published in the international journal European Urology Oncology.
The study presents findings from a multicentric retrospective data analysis examining the efficacy of metastasis-directed radiotherapy with or without androgen deprivation therapy in patients with oligometastatic prostate cancer. Remarkably, the research demonstrates that integrating androgen deprivation therapy with metastasis-directed therapy leads to improved progression-free survival. Congratulations Prof. Silke Gillessen, Dr. Davide Bosetti and all authors!
Link to the article.”

Source: IOSI Oncology Institute of Southern Switzerland – EOC/LinkedIn

androgen deprivation therapy cancer Dr. Davide Bosetti European Urology Oncology IOSI Istituto Oncologico della Svizzera Italiana - EOC IOSI Oncology Institute of Southern Switzerland - EOC metastasis-directed radiotherapy oligometastatic prostate cancer OncoDaily Oncology Prof. Silke Gillessen Research

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology